Artenga’s microbubble drug conjugates (MDC) and focused ultrasound (FUS) are key enablers for:

  • Safe, non-invasive, targeted blood brain barrier drug delivery
  • Boosting immunotherapy efficacy without added toxicity
  • Our Sunnybrook collaborators did first clinical FUS and non-drug microbubble BBB opening for glioblastoma, Alzheimer’s, breast cancer, brain mets, ALS and Parkinson’s.

Differentiation factors are:

  • Higher dose delivered with greater perfusion
  • Liver clearance to mitigate systemic effects
  • AAV MDC and new tech planned to limit transduction to diseased brain regions
Artenga Inc.  Logo



Event details

Date: September 13 - 15, 2021

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


6 in total